Alan Musso
Director of Finance/CFO at FULCRUM THERAPEUTICS, INC.
Net worth: - $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Manuel Alves Aivado | M | 53 | 10 years | |
| Robert Gould | M | 69 | - | |
| Paul Romness | M | 57 |
OS Therapies, Inc.
 OS Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services OS Therapies, Inc. operates as a clinical stage biopharmaceutical company. It engages in identification, development, and commercialization of treatments for Osteosarcoma and other related diseases. The company was founded by Paul A. Romness on April 12, 2018 and is headquartered in Rockville, MD. | 6 years |
| Brian Windsor | M | 57 | 1 years | |
| Alexander Sapir | M | 57 | 1 years | |
| Richard Fair | M | 55 | 7 years | |
| Kathryn Haviland | F | 48 | 6 years | |
| Josef H. Von Rickenbach | M | 68 | 5 years | |
| Iain Fraser | M | - | 1 years | |
| David Annis | M | 51 | 17 years | |
| Sonja Banks | F | 55 | 3 years | |
| Mel Hayes | M | 54 | 3 years | |
| Liz Melone | F | - | - | |
| James Geraghty | M | 69 | 8 years | |
| William Fairey | M | 60 | 1 years | |
| Reinhard Ambros | M | 67 | 11 years | |
| Katina Dorton | F | 66 | 4 years | |
| R. Alan B. Ezekowitz | M | 70 | 8 years | |
| James Collins | M | 58 | 7 years | |
| Leslie Leinwand | M | - | - | |
| Joacim Borg | M | 32 |
OS Therapies, Inc.
OS Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services OS Therapies, Inc. operates as a clinical stage biopharmaceutical company. It engages in identification, development, and commercialization of treatments for Osteosarcoma and other related diseases. The company was founded by Paul A. Romness on April 12, 2018 and is headquartered in Rockville, MD. | 2 years |
| Kristina Storey | F | - | 2 years | |
| Jack Doll | M | - |
OS Therapies, Inc.
OS Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services OS Therapies, Inc. operates as a clinical stage biopharmaceutical company. It engages in identification, development, and commercialization of treatments for Osteosarcoma and other related diseases. The company was founded by Paul A. Romness on April 12, 2018 and is headquartered in Rockville, MD. | - |
| Dee Smith | M | - | - | |
| Paul Bruno | M | - | 5 years | |
| Gregory Tourangeau | M | - | 2 years | |
| Mani Sundararajan | M | - | 3 years | |
| Robert G. Petit | M | 64 |
OS Therapies, Inc.
OS Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services OS Therapies, Inc. operates as a clinical stage biopharmaceutical company. It engages in identification, development, and commercialization of treatments for Osteosarcoma and other related diseases. The company was founded by Paul A. Romness on April 12, 2018 and is headquartered in Rockville, MD. | 5 years |
| Colin Goddard | M | 64 |
OS Therapies, Inc.
OS Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services OS Therapies, Inc. operates as a clinical stage biopharmaceutical company. It engages in identification, development, and commercialization of treatments for Osteosarcoma and other related diseases. The company was founded by Paul A. Romness on April 12, 2018 and is headquartered in Rockville, MD. | 4 years |
| Curtis Oltmans | M | 60 | 4 years | |
| Kim Hazen | F | - | 7 years | |
| John Ciccio | M | 43 |
OS Therapies, Inc.
OS Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services OS Therapies, Inc. operates as a clinical stage biopharmaceutical company. It engages in identification, development, and commercialization of treatments for Osteosarcoma and other related diseases. The company was founded by Paul A. Romness on April 12, 2018 and is headquartered in Rockville, MD. | 4 years |
| Theodore F. Search | M | 42 |
OS Therapies, Inc.
OS Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services OS Therapies, Inc. operates as a clinical stage biopharmaceutical company. It engages in identification, development, and commercialization of treatments for Osteosarcoma and other related diseases. The company was founded by Paul A. Romness on April 12, 2018 and is headquartered in Rockville, MD. | 4 years |
| Jeffrey W. Jacobs | M | 61 | 2 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Joseph deBethizy | M | 74 |
Targacept, Inc.
 Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | 15 years |
| Kevin M. Slawin | M | 63 | 13 years | |
| Thomas J. Farrell | M | 60 | 11 years | |
| Stephen Hill | M | 65 |
Targacept, Inc.
Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | 3 years |
| John P. Richard | M | 66 |
Targacept, Inc.
Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | 13 years |
| Charles T. Garner | M | 48 | 1 years | |
| Jon Stonehouse | M | 63 | 10 years | |
| John Josey | M | 63 | 8 years | |
| Mark B. Skaletsky | M | 75 |
Targacept, Inc.
Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | 12 years |
| G. Steven Burrill | M | 79 |
Targacept, Inc.
Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | 13 years |
| Alan K. Smith | M | 68 | 5 years | |
| Annemarie B. Moseley | M | 68 | 6 years | |
| Julia Brown | F | 76 |
Targacept, Inc.
Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | - |
| Edmund Harrigan | M | 71 | 1 years | |
| Michael Barrett | M | 81 |
Targacept, Inc.
Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | 11 years |
| Jeffrey Bailey | M | 62 | 5 years | |
| Steven M. Toler | M | 63 |
Targacept, Inc.
Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | 11 years |
| Shane Ward | M | 49 | 2 years | |
| Thilo Schroeder | M | 42 | 5 years | |
| Susan Drexler | F | 54 | 2 years | |
| James Daly | M | 63 | 8 years | |
| Jodie Morrison | F | 48 | 6 years | |
| Patrick C. Rock | M | 64 |
Targacept, Inc.
Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | - |
| Peter A. Zorn | M | 53 |
Targacept, Inc.
Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | 10 years |
| John Moore | M | 59 | 1 years | |
| Geoffrey C. Dunbar | M | 77 |
Targacept, Inc.
Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | 11 years |
| Errol de Souza | M | 70 |
Targacept, Inc.
Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | 11 years |
| Alan Dunton | M | 70 |
Targacept, Inc.
Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | 9 years |
| William McKee | M | 62 | 4 years | |
| Nolan Sigal | M | 73 | 5 years | |
| Stephen Davis | M | 63 | 9 years | |
| Ralph Snyderman | M | 84 |
Targacept, Inc.
Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | 6 years |
| Tom Siino | M | - |
St. Mary's College of California
| 4 years |
| Peter Hoang | M | 52 | 3 years | |
| John E. Donahue | M | - |
St. Mary's College of California
| 5 years |
| Anne Frese | F | - | 3 years | |
| Mark J. Madgett | M | 62 |
St. Mary's College of California
| 4 years |
| Steven Neeley | M | - |
Thunderbird School of Global Management
| 3 years |
| Tsvetelina Pencheva Hoang | M | 51 | 3 years | |
| Mark Steed | M | - |
Thunderbird School of Global Management
| 1 years |
| William R. Sellers | M | 63 | 2 years | |
| Joseph Woodard | M | 58 | 2 years | |
| Jaa Roberson | F | - | 2 years | |
| Romi S Dhillon | M | - |
Thunderbird School of Global Management
| 1 years |
| Jenny Chaplin | F | - | 5 years | |
| Kelly Mullaney Dean | F | - |
St. Mary's College of California
| 4 years |
| Shawn F. Flaherty | M | - |
St. Mary's College of California
| 4 years |
| Stefan Michel | M | 57 |
Thunderbird School of Global Management
| 5 years |
| Chu Shan Chen | M | 42 |
Thunderbird School of Global Management
| 2 years |
| Richard Alexander Lewis | M | - |
St. Mary's College of California
| 1 years |
| Steven J. Winick | M | - | - | |
| Don Evenson | M | - |
St. Mary's College of California
| 4 years |
| Earl Sands | M | 66 |
Targacept, Inc.
Targacept, Inc. Pharmaceuticals: OtherHealth Technology Targacept, Inc. is a biopharmaceutical company, which is engaged in the design, discovery and development of a new class of drugs to treat multiple diseases and disorders of the nervous system by selectively targeting Neuronal Nicotinic Receptors, or NNRs. NNRs are found on nerve cells throughout the human nervous system and serve as key regulators of nervous system activity. Targacept was founded by J. Donald deBethizy, Merouane Bencherif, William S. Caldwell and Patrick M. Lippiello on March 7, 1997 and is headquartered in Winston-Salem, NC. | 1 years |
| Gregory S. Naeve | M | 60 | 2 years | |
| Micheline Bouchard | F | 76 |
Thunderbird School of Global Management
| 5 years |
| Nancy Reggio | F | - |
St. Mary's College of California
| 4 years |
| Charles B. Conner | M | - |
Thunderbird School of Global Management
| 1 years |
| James O'Malley | M | - |
Thunderbird School of Global Management
| 2 years |
| Scott N. Cullison | M | - | 3 years | |
| Allie Burns | F | - |
Thunderbird School of Global Management
| 2 years |
| Frank Scardena | M | - |
Thunderbird School of Global Management
| 2 years |
| Tim Coughlin | M | 57 | - | |
| Joel Montgomery | M | - |
Thunderbird School of Global Management
| 2 years |
| Eric H. Miscoll | M | 61 |
St. Mary's College of California
| 4 years |
| Shang Ting Huang | F | - |
Thunderbird School of Global Management
| 2 years |
| Steve Clegg | M | - |
Thunderbird School of Global Management
| 1 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Alan Musso
- Personal Network